Form 4: STERIS plc Executive Reports Routine Stock Vesting and Tax-Related Share Disposition

Julia Madsen, Sr. VP and GM of Life Sciences at STERIS plc, reported the vesting of restricted shares and the subsequent disposition of a portion of these shares to cover tax obligations.

Summary

• Julia Madsen, Senior Vice President and General Manager of Life Sciences at STERIS plc, filed a Form 4 detailing changes in her beneficial ownership.
• On June 4, 2025, 542 restricted ordinary shares vested, which were originally awarded on June 4, 2024.
• Concurrently, 194 ordinary shares were withheld by the Issuer at a price of $242.1 per share to satisfy tax withholding requirements related to the vesting.
• Following this transaction, Ms. Madsen beneficially owns 10,762 ordinary shares of STERIS plc.
• Of the beneficially owned shares, 4,147 remain restricted with various vesting schedules extending through June 5, 2028.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were 'disposed of', it was a non-discretionary transaction for tax purposes following the vesting of restricted stock, which is a positive event for the executive and a routine part of compensation.

Positives

• The vesting of 542 restricted shares indicates the fulfillment of long-term incentive compensation for a key executive.
• The continued beneficial ownership of 10,762 shares, with a significant portion still restricted, aligns executive incentives with long-term shareholder value.

Negatives

• 194 shares were disposed of, reducing the total number of shares held, although this was a non-discretionary transaction for tax purposes.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as its purpose is to report changes in beneficial ownership of securities.

Management Comments

• The transaction reflects the standard process for executive compensation, where restricted stock units vest and a portion is withheld to cover statutory tax obligations.

Industry Context

Form 4 filings are routine disclosures in the U.S. financial markets, providing transparency into insider transactions. The reported transaction, involving the vesting of restricted stock and subsequent tax withholding, is a common practice in executive compensation across various industries, including the healthcare and life sciences sectors where STERIS plc operates.

Comparison to Industry Standards

• The mechanism of restricted stock unit (RSU) awards with tax withholding upon vesting is a standard component of executive compensation packages across publicly traded companies, including peers in the medical device and healthcare services industry such as Medtronic (MDT), Stryker (SYK), and Danaher (DHR).
• The reported share price of $242.1 for the tax withholding is consistent with market-based valuations for such transactions.

Stakeholder Impact

• Shareholders: This is a routine insider transaction related to executive compensation and tax obligations, not indicative of a change in company fundamentals or strategy. It provides transparency into executive stock ownership.
• Employees: The vesting of restricted shares is a common form of long-term incentive compensation, which can positively impact employee morale and retention, particularly for senior executives.

Next Steps

• Future vesting of remaining restricted shares held by Ms. Madsen on various dates: 144 shares on October 1, 2025; 578 shares on June 1, 2026; 352 shares on June 2, 2026; 666 shares on June 3, 2026; 542 shares on June 4, 2026; 666 shares on June 3, 2027; 542 shares on June 4, 2027; and 666 shares on June 5, 2028.

Key Dates

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation, Stock Vesting, Tax Withholding